- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
- Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
- Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Friday, Phathom Pharmaceuticals Inc (PHAT:NSQ) closed at 9.42, 55.32% above the 52 week low of 6.07 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.23 |
---|---|
High | 10.43 |
Low | 9.23 |
Bid | 9.26 |
Offer | 10.41 |
Previous close | 10.19 |
Average volume | 497.66k |
---|---|
Shares outstanding | 58.54m |
Free float | 52.83m |
P/E (TTM) | -- |
Market cap | 551.40m USD |
EPS (TTM) | -4.41 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼